<!doctype html><html lang="zh-hans"><head><meta charset="utf-8"><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"><title>FDA官员要求在争议的阿尔茨海默氏药物批准后下降 FDA officials asked to step down after contentious Alzheimer’s drug approval</title><link rel="stylesheet" href="https://stackpath.bootstrapcdn.com/bootstrap/4.3.1/css/bootstrap.min.css" integrity="sha384-ggOyR0iXCbMQv3Xipma34MD+dH/1fQ784/j6cY/iJTQUOhcWr7x9JvoRxT2MZw1T" crossorigin="anonymous"><link rel="stylesheet" href="/img/css.css?random="><link data-rh="true" rel="icon" href="/img/favicon.ico"/><script data-ad-client="ca-pub-6067137220025946" async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script><script type="text/javascript" src="https://platform-api.sharethis.com/js/sharethis.js#property=5effb96910009800120b8d4d&product=inline-share-buttons" async="async"></script>
<script>var _hmt = _hmt || [];(function() {var hm = document.createElement("script");hm.src = "https://hm.baidu.com/hm.js?03c1a0f31299b4a2fbb83c34d6beaac9";var s = document.getElementsByTagName("script")[0]; s.parentNode.insertBefore(hm, s);})();</script></head><body><div id="my_header"><div class="container"><nav class="navbar navbar-expand-lg"><a class="navbar-brand" href="/"><img alt="diglog" src="/img/logo.v1.gif" class="rounded-sm"></a><button class="navbar-toggler" type="button" data-toggle="collapse" data-target="#navbarNavAltMarkup" aria-controls="navbarNavAltMarkup" aria-expanded="false" aria-label="Toggle navigation"><span class="navbar-toggler-icon"></span></button><div class="collapse navbar-collapse" id="navbarNavAltMarkup"><div class="navbar-nav"></div></div></nav></div></div><div class="container"><div id="my_content"><h1 class="page_narrow">FDA officials asked to step down after contentious Alzheimer’s drug approval<br/>FDA官员要求在争议的阿尔茨海默氏药物批准后下降 </h1><div class="row"><div class="col-lg-12 col-12"><div class="my_story_list_item shadow p-3 mb-5 bg-white rounded"><div class="story_page_pub_time page_narrow">2021-06-18 03:40:22</div><div class="story_img_container"><a href="http://img2.diglog.com/img/2021/6/4d923f074dde637fe0a7fe068b8ab6c3.jpg"><img src="http://img2.diglog.com/img/2021/6/4d923f074dde637fe0a7fe068b8ab6c3.jpg" class="img-fluid my_story_img" onerror="this.style.display='none'"></a></div><div class="page_narrow text-break page_content"><p>A leading advocacy and watchdog group is  calling for the ouster of three top officials at the Food and Drug Administration—including its acting commissioner—after the regulator issued a highly contentious approval last week of the unproven and now highly priced Alzheimer’s drug Aduhelm (generic name: aducanumab).</p><p>领先的宣传和看门狗小组正在呼吁在食品和药物管理局的三个顶级官员的欧斯特 - 包括其代理专员 - 在监管机构上周发布了一个令人讨厌的批准，上周的未经证实，现在是高度价格的阿尔茨海默氏药物Aduhelm（通用名称：Aducanumab）。</p><p> The call for fresh FDA leadership comes atop a chorus of harsh criticism over the decision, which outside researchers and industry experts have called  “disgraceful” and “dangerous,” among other things.</p><p> 新鲜FDA领导的呼吁在决定上at atop批评的批评，除其他事物之外的研究人员和行业专家们呼吁“可耻”和“危险”。</p><p> Since Aduhelm’s approval was announced June 7,  three expert advisers to the FDA have resigned in protest, with one calling the decision “probably the worst drug-approval decision in recent US history.” The three experts were part of an 11-member advisory committee that reviewed the clinical data for the Alzheimer’s drug last November and voted nearly unanimously  against approval (10 voted against, 1 voted “uncertain”).</p><p> 由于Aduhelm批准于6月7日宣布，FDA的三位专家顾问们倾向于抗议，其中一个呼吁决定“可能是最近美国历史上最糟糕的药品批准决定”。这三位专家是一个11人咨询委员会的一部分，审查了去年11月的阿尔茨海默氏药物的临床资料，并反对批准绩效几乎一致（10投票，1投票的“不确定”）。</p><p> On Wednesday, advocacy group Public Citizen only increased the din of criticism, calling the FDA’s approval “reckless.” The FDA’s decision “showed a stunning disregard for science, eviscerated the agency’s standards for approving new drugs, and ranks as one of the most irresponsible and egregious decisions in the history of the agency,” Michael Carome, director of Public Citizen’s Health Research Group, said in a statement. “The sheer recklessness of the FDA’s approval of aducanumab cannot be overstated. This decision is a disastrous blow to the agency’s credibility, public health and the financial sustainability of the Medicare program.” The latter point refers to the fact that Aduhelm’s developer, Biogen, set the drug’s list price at $56,000 for a year’s supply.</p><p> 周三，宣传小组公民只会增加批评的喧嚣，呼吁FDA的批准“鲁莽”。 FDA的决定“表明，令人惊叹的科学忽视，嘲笑原子能机构批准新药的标准，并作为原子能机构历史上最不负责任和令人震惊的决定之一，”公共公民卫生研究组主任Michael Carome，在一份声明中说。 “FDA对Aducanumab批准的纯粹鲁莽不能夸大。这一决定是对原子能机构的可信度，公共卫生和医疗保险计划的金融可持续性的灾难性打击。“后一点是指Aduhelm的开发人员Biogen，将药物的名单价格设定为56,000美元，为每年供应量为56,000美元。</p><p> In  a letter addressed to Xavier Becerra, secretary of the Department of Health and Human Services, Dr. Carome and Public Citizen called for the immediate resignation or removal of three top FDA officials, whom they described as “most responsible” for the approval. They are: acting FDA Commissioner Janet Woodcock, Center for Drug Evaluation and Research (CDER) Director Patrizia Cavazzoni, and CDER Office of Neuroscience (ON) Director Billy Dunn.</p><p> 在卫生和人类服务部的秘书向Xavier Becerra致函的一封信中，凯洛和公民博士呼吁立即辞职或删除三大FDA官员，他们被描述为批准的“最负责任”。它们是：代理FDA专员Janet Woodcock，药物评估中心和研究中心（CDER）主任Patrizia Cavazzoni，以及神经科学的CDER办公室（ON）总监Billy Dunn。</p><p>    “New leadership of the FDA and CDER is a prerequisite for restoring the agency’s credibility and reversing the slide in the agency’s standards for ensuring the safety and effectiveness of new drugs,” Carome said in the letter. “You should direct the next Acting FDA Commissioner to consider whether the agency’s approval of Biogen’s BLA for aducanumab should be withdrawn.”</p><p>    “FDA和CDER的新领导是恢复原子能机构信誉，并扭转原子能机构的标准的幻灯片的先决条件，以确保新药的安全和有效性，”在信中说。 “你应该指导下一个代理FDA专员考虑原子能机构是否应该撤回原子能机构Bla Bla的批准。”</p><p>  Though the fiery letter noted that there was a “litany of flaws” behind the FDA’s decision, it laid out four critical problems with the approval. Those four problems echo the criticisms brought up by other experts and the FDA’s advisory committee before and after the approval.</p><p>  虽然火热的信指出，FDA的决定背后有一个“瑕疵”，但它批准了四个关键问题。这四个问题回应了其他专家和FDA咨询委员会在批准之前和批准后所提出的批评。 </p><p>  “The unprecedented, inappropriately close collaboration” between the FDA and Aduhelm’s maker, Biogen, which “dangerously compromised the independence and objectivity of the agency’s review.”</p><p>“前所未有的，不恰当地密切合作”生物原生物因，“危险地损害了原子能机构审查的独立性和客观性”。</p><p> The fact that the approval was unexpectedly based on an “unvalidated” surrogate endpoint—reduction of amyloid-beta plaques in the brain—rather than efficacy. The FDA had stated very clearly to its advisers in November that it would base the decision on efficacy and not use this surrogate endpoint for approval. But, upon approval, the regulator said that it did use the surrogate and claimed that the reduction of amyloid-beta is   expected to lead to clinical benefit. Public Citizen and many outside experts note that evidence from the Aduhelm trials and many other trials have found no correlation between reduction in amyloid-beta plaques and improvement in cognitive function. (FDA’s own statisticians, the expert advisers, and many outside experts all agreed that Biogen’s trial data did not clearly indicate that the drug was effective at improving cognitive function. The FDA acknowledged the “uncertainty” about efficacy and based the approval on the surrogate instead.)</p><p> 批准的事实意外地基于脑中淀粉样蛋白蛋白蛋白蛋白蛋白蛋白蛋白蛋白蛋白的蛋白蛋白斑块而不是疗效。 FDA在11月份对其顾问表示明确表示，它将根据疗效决定并没有使用此代理终点进行批准。但是，在批准后，监管机构表示，它确实使用替代物并声称降低淀粉样蛋白β的降低导致临床效益。公共公民和许多外部专家都指出，来自Aduhelm试验和许多其他试验的证据发现淀粉样蛋白β斑块的降低与认知功能的改善之间没有相关性。 （FDA自己的统计学家，专家顾问和许多外部专家都同意Biogen的试验数据没有明确表明该药物在改善认知功能方面有效。FDA认识到关于疗效的“不确定性”，并基于代理人的批准。）</p><p> The apparent disregard of the FDA advisers who voted against approval and the FDA’s decision not to seek their input on the use of the surrogate endpoint.</p><p> 明显无视投票反对批准的FDA顾问和FDA的决定不寻求他们对使用代理终点的意见。</p><p> And, lastly, approving Aduhelm for all types of Alzheimer’s disease patients despite the fact that Biogen’s trials only included patients with mild disease.</p><p> 并且，最后，尽管生物原激发只包括轻度疾病的患者，但仍然批准所有类型的阿尔茨海默病患者的Aduhelm。</p><p> While many critics of the FDA’s decision have expressed concern for the precedent the approval sets for future drugs, Public Citizen and others also worry about the impacts on patients and their families.</p><p> 虽然FDA的许多批评者对未来药物，公共公民和其他人的批准套装表示关切，但也担心对患者及其家庭的影响。</p><p> “Approving aducanumab despite the lack of evidence of effectiveness has raised false hope for millions of Alzheimer’s disease patients and their families… and will impede for years the development of other experimental treatments for this devastating disease,” Carome wrote.</p><p> “尽管缺乏有效性证据表明，批准了伊索曼姆，但为数百万阿尔茨海默病患者及其家属提高了虚假希望......并将阻碍这种毁灭性疾病的其他实验治疗的发展，”凯马写道。 </p></div><div id="story_share_this"><div class="sharethis-inline-share-buttons"></div></div><div class="text-break sotry_link page_narrow"><a target="_blank" href="https://arstechnica.com/science/2021/06/advocacy-org-calls-for-ouster-of-fda-officials-after-alzheimers-drug-approval/">https://arstechnica.com/science/2021/06/advocacy-org-calls-for-ouster-of-fda-officials-after-alzheimers-drug-approval/</a></div><div class="story_tags page_narrow"><button type="button" class="btn btn-light my_tag"><a href="/tag/官员/">#官员</a></button><button type="button" class="btn btn-light my_tag"><a href="/tag/officials/">#officials</a></button><button type="button" class="btn btn-light my_tag"><a href="/tag/批准/">#批准</a></button></div></div><div class="my_movie_list_item shadow p-3 mb-5 bg-white rounded"><button type="button" class="btn btn-link my_tag"><a href="/tag/web2.0/">#web2.0</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/google/">#google</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/设计/">#设计</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/创意/">#创意</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/摄影/">#摄影</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/图片/">#图片</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/游戏/">#游戏</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/软件/">#软件</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/视频/">#视频</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/手机/">#手机</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/广告/">#广告</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/windows/">#windows</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/iphone/">#iphone</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/免费/">#免费</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/网站/">#网站</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/下载/">#下载</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/微软/">#微软</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/blog/">#blog</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/firefox/">#firefox</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/音乐/">#音乐</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/苹果/">#苹果</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/apple/">#apple</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/博客/">#博客</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/wordpress/">#wordpress</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/恶搞/">#恶搞</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/艺术/">#艺术</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/qq/">#qq</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/谷歌/">#谷歌</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/web/">#web</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/工具/">#工具</a></button></div></div></div><div id="my_footer"><div class=""><a href="/tags/">tags</a> <a href="/users/">users</a></div>&copy;2012-2021 diglog.com </div></div></body></html>